<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p246" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_246{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_246{left:306px;bottom:30px;}
#t3_246{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_246{left:346px;bottom:30px;}
#t5_246{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_246{left:517px;bottom:30px;}
#t7_246{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_246{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_246{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_246{left:1105px;bottom:27px;letter-spacing:0.25px;}
#tb_246{left:35px;bottom:777px;letter-spacing:0.03px;word-spacing:0.16px;}
#tc_246{left:35px;bottom:759px;letter-spacing:0.06px;word-spacing:0.12px;}
#td_246{left:35px;bottom:739px;letter-spacing:0.16px;}
#te_246{left:405px;bottom:739px;}
#tf_246{left:35px;bottom:702px;letter-spacing:0.03px;word-spacing:0.16px;}
#tg_246{left:35px;bottom:683px;letter-spacing:0.09px;word-spacing:0.1px;}
#th_246{left:35px;bottom:665px;letter-spacing:0.04px;word-spacing:0.15px;}
#ti_246{left:35px;bottom:645px;letter-spacing:0.06px;word-spacing:0.12px;}
#tj_246{left:35px;bottom:625px;letter-spacing:0.16px;}
#tk_246{left:405px;bottom:625px;}
#tl_246{left:35px;bottom:589px;letter-spacing:-0.03px;word-spacing:-0.41px;}
#tm_246{left:35px;bottom:570px;letter-spacing:0.14px;word-spacing:0.05px;}
#tn_246{left:35px;bottom:551px;letter-spacing:0.14px;word-spacing:0.05px;}
#to_246{left:35px;bottom:531px;letter-spacing:0.1px;word-spacing:0.09px;}
#tp_246{left:35px;bottom:512px;letter-spacing:0.16px;}
#tq_246{left:405px;bottom:512px;}
#tr_246{left:35px;bottom:476px;letter-spacing:0.03px;word-spacing:-0.67px;}
#ts_246{left:35px;bottom:457px;letter-spacing:0.12px;word-spacing:-0.67px;}
#tt_246{left:35px;bottom:437px;letter-spacing:0.01px;word-spacing:0.18px;}
#tu_246{left:35px;bottom:418px;letter-spacing:0.1px;word-spacing:0.09px;}
#tv_246{left:35px;bottom:398px;letter-spacing:0.16px;}
#tw_246{left:396px;bottom:398px;}
#tx_246{left:35px;bottom:363px;letter-spacing:0.05px;word-spacing:-0.35px;}
#ty_246{left:35px;bottom:343px;letter-spacing:0.13px;word-spacing:0.05px;}
#tz_246{left:35px;bottom:324px;letter-spacing:0.03px;word-spacing:0.15px;}
#t10_246{left:35px;bottom:304px;letter-spacing:0.09px;word-spacing:0.09px;}
#t11_246{left:35px;bottom:284px;letter-spacing:0.15px;}
#t12_246{left:395px;bottom:284px;}
#t13_246{left:35px;bottom:249px;letter-spacing:0.01px;word-spacing:0.18px;}
#t14_246{left:35px;bottom:229px;letter-spacing:0.08px;word-spacing:-0.92px;}
#t15_246{left:35px;bottom:210px;letter-spacing:0.08px;word-spacing:0.1px;}
#t16_246{left:35px;bottom:190px;letter-spacing:0.16px;}
#t17_246{left:405px;bottom:190px;}
#t18_246{left:35px;bottom:155px;letter-spacing:0.1px;word-spacing:-0.53px;}
#t19_246{left:35px;bottom:135px;letter-spacing:0.08px;word-spacing:-0.36px;}
#t1a_246{left:35px;bottom:116px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1b_246{left:35px;bottom:96px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1c_246{left:35px;bottom:77px;letter-spacing:0.16px;}
#t1d_246{left:405px;bottom:77px;}
#t1e_246{left:618px;bottom:777px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1f_246{left:618px;bottom:759px;letter-spacing:0.03px;word-spacing:-0.86px;}
#t1g_246{left:618px;bottom:739px;letter-spacing:0.08px;word-spacing:-1.12px;}
#t1h_246{left:618px;bottom:720px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t1i_246{left:715px;bottom:720px;letter-spacing:0.16px;}
#t1j_246{left:1084px;bottom:720px;}
#t1k_246{left:618px;bottom:683px;letter-spacing:0.15px;word-spacing:-0.11px;}
#t1l_246{left:618px;bottom:665px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1m_246{left:618px;bottom:645px;letter-spacing:0.16px;}
#t1n_246{left:979px;bottom:645px;}
#t1o_246{left:618px;bottom:608px;letter-spacing:0.03px;word-spacing:-1.07px;}
#t1p_246{left:618px;bottom:589px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1q_246{left:618px;bottom:570px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1r_246{left:618px;bottom:551px;letter-spacing:0.16px;}
#t1s_246{left:979px;bottom:551px;}
#t1t_246{left:618px;bottom:514px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1u_246{left:618px;bottom:495px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1v_246{left:618px;bottom:476px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1w_246{left:618px;bottom:457px;letter-spacing:0.16px;}
#t1x_246{left:969px;bottom:457px;}
#t1y_246{left:618px;bottom:420px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1z_246{left:618px;bottom:401px;letter-spacing:0.1px;word-spacing:0.09px;}
#t20_246{left:618px;bottom:382px;letter-spacing:0.15px;word-spacing:0.03px;}
#t21_246{left:618px;bottom:363px;word-spacing:0.19px;}
#t22_246{left:618px;bottom:343px;letter-spacing:0.13px;word-spacing:0.06px;}
#t23_246{left:618px;bottom:324px;letter-spacing:0.09px;word-spacing:0.1px;}
#t24_246{left:618px;bottom:304px;letter-spacing:0.16px;}
#t25_246{left:969px;bottom:304px;}
#t26_246{left:618px;bottom:269px;letter-spacing:0.02px;word-spacing:0.17px;}
#t27_246{left:618px;bottom:249px;letter-spacing:0.06px;word-spacing:0.13px;}
#t28_246{left:618px;bottom:229px;letter-spacing:0.11px;word-spacing:0.08px;}
#t29_246{left:618px;bottom:210px;letter-spacing:0.16px;}
#t2a_246{left:979px;bottom:210px;}
#t2b_246{left:618px;bottom:174px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2c_246{left:618px;bottom:155px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2d_246{left:618px;bottom:135px;letter-spacing:-0.01px;word-spacing:0.2px;}
#t2e_246{left:618px;bottom:116px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2f_246{left:618px;bottom:96px;letter-spacing:-0.07px;word-spacing:0.25px;}
#t2g_246{left:763px;bottom:96px;letter-spacing:0.16px;}
#t2h_246{left:1132px;bottom:96px;}
#t2i_246{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_246{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_246{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_246{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_246{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_246{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_246{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_246{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts246" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg246Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg246" style="-webkit-user-select: none;"><object width="1210" height="935" data="246/246.svg" type="image/svg+xml" id="pdf246" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_246" class="t s0_246">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_246" class="t s1_246">© </span>
<span id="t3_246" class="t s0_246">(NCCN </span>
<span id="t4_246" class="t s1_246">© </span>
<span id="t5_246" class="t s0_246">), All rights reserved. NCCN Guidelines </span>
<span id="t6_246" class="t s1_246">® </span>
<span id="t7_246" class="t s0_246">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_246" class="t s2_246">NCCN Guidelines Version 4.2024 </span>
<span id="t9_246" class="t s2_246">Head and Neck Cancers </span>
<span id="ta_246" class="t s3_246">MS-105 </span>
<span id="tb_246" class="t s4_246">cisplatin for locally advanced head and neck cancer. Head Neck </span>
<span id="tc_246" class="t s4_246">2005;27:36-43. Available at: </span>
<span id="td_246" class="t s5_246">https://www.ncbi.nlm.nih.gov/pubmed/15459918</span><span id="te_246" class="t s4_246">. </span>
<span id="tf_246" class="t s4_246">624. Medina JA, Rueda A, de Pasos AS, et al. A phase II study of </span>
<span id="tg_246" class="t s4_246">concomitant boost radiation plus concurrent weekly cisplatin for locally </span>
<span id="th_246" class="t s4_246">advanced unresectable head and neck carcinomas. Radiother Oncol </span>
<span id="ti_246" class="t s4_246">2006;79:34-38. Available at: </span>
<span id="tj_246" class="t s5_246">https://www.ncbi.nlm.nih.gov/pubmed/16626826</span><span id="tk_246" class="t s4_246">. </span>
<span id="tl_246" class="t s4_246">625. Kiyota N, Tahara M, Mizusawa J, et al. Weekly cisplatin plus radiation </span>
<span id="tm_246" class="t s4_246">for postoperative head and neck cancer (JCOG1008): a multicenter, </span>
<span id="tn_246" class="t s4_246">noninferiority, phase II/III randomized controlled trial. J Clin Oncol </span>
<span id="to_246" class="t s4_246">2022;40:1980-1990. Available at: </span>
<span id="tp_246" class="t s5_246">https://www.ncbi.nlm.nih.gov/pubmed/35230884</span><span id="tq_246" class="t s4_246">. </span>
<span id="tr_246" class="t s4_246">626. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation </span>
<span id="ts_246" class="t s4_246">Therapy Oncology Group 97-03: a randomized phase II trial of concurrent </span>
<span id="tt_246" class="t s4_246">radiation and chemotherapy for advanced squamous cell carcinomas of </span>
<span id="tu_246" class="t s4_246">the head and neck. J Clin Oncol 2004;22:2856-2864. Available at: </span>
<span id="tv_246" class="t s5_246">http://www.ncbi.nlm.nih.gov/pubmed/15254053</span><span id="tw_246" class="t s4_246">. </span>
<span id="tx_246" class="t s4_246">627. Taylor SG, Murthy AK, Vannetzel JM, et al. Randomized comparison </span>
<span id="ty_246" class="t s4_246">of neoadjuvant cisplatin and fluorouracil infusion followed by radiation </span>
<span id="tz_246" class="t s4_246">versus concomitant treatment in advanced head and neck cancer. J Clin </span>
<span id="t10_246" class="t s4_246">Oncol 1994;12:385-395. Available at: </span>
<span id="t11_246" class="t s5_246">https://www.ncbi.nlm.nih.gov/pubmed/8113846</span><span id="t12_246" class="t s4_246">. </span>
<span id="t13_246" class="t s4_246">628. Sun XS, Michel C, Babin E, et al. Approach to oligometastatic </span>
<span id="t14_246" class="t s4_246">disease in head and neck cancer, on behalf of the GORTEC. Future Oncol </span>
<span id="t15_246" class="t s4_246">2018;14:877-889. Available at: </span>
<span id="t16_246" class="t s5_246">https://www.ncbi.nlm.nih.gov/pubmed/29578359</span><span id="t17_246" class="t s4_246">. </span>
<span id="t18_246" class="t s4_246">629. Bonomo P, Greto D, Desideri I, et al. Clinical outcome of stereotactic </span>
<span id="t19_246" class="t s4_246">body radiotherapy for lung-only oligometastatic head and neck squamous </span>
<span id="t1a_246" class="t s4_246">cell carcinoma: Is the deferral of systemic therapy a potential goal? Oral </span>
<span id="t1b_246" class="t s4_246">Oncol 2019;93:1-7. Available at: </span>
<span id="t1c_246" class="t s5_246">https://www.ncbi.nlm.nih.gov/pubmed/31109688</span><span id="t1d_246" class="t s4_246">. </span>
<span id="t1e_246" class="t s4_246">630. Bates JE, De Leo AN, Morris CG, et al. Oligometastatic squamous </span>
<span id="t1f_246" class="t s4_246">cell carcinoma of the head and neck treated with stereotactic body ablative </span>
<span id="t1g_246" class="t s4_246">radiotherapy: single-institution outcomes. Head Neck 2019;41:2309-2314. </span>
<span id="t1h_246" class="t s4_246">Available at: </span><span id="t1i_246" class="t s5_246">https://www.ncbi.nlm.nih.gov/pubmed/30788878</span><span id="t1j_246" class="t s4_246">. </span>
<span id="t1k_246" class="t s4_246">631. Molin Y, Fayette J. Current chemotherapies for recurrent/metastatic </span>
<span id="t1l_246" class="t s4_246">head and neck cancer. Anticancer Drugs 2011;22:621-625. Available at: </span>
<span id="t1m_246" class="t s5_246">http://www.ncbi.nlm.nih.gov/pubmed/21131821</span><span id="t1n_246" class="t s4_246">. </span>
<span id="t1o_246" class="t s4_246">632. Hoffmann TK. Systemic therapy strategies for head-neck carcinomas: </span>
<span id="t1p_246" class="t s4_246">Current status. GMS Curr Top Otorhinolaryngol Head Neck Surg </span>
<span id="t1q_246" class="t s4_246">2012;11:Doc03. Available at: </span>
<span id="t1r_246" class="t s5_246">http://www.ncbi.nlm.nih.gov/pubmed/23320055</span><span id="t1s_246" class="t s4_246">. </span>
<span id="t1t_246" class="t s4_246">633. Browman GP, Cronin L. Standard chemotherapy in squamous cell </span>
<span id="t1u_246" class="t s4_246">head and neck cancer: what we have learned from randomized trials. </span>
<span id="t1v_246" class="t s4_246">Semin Oncol 1994;21:311-319. Available at: </span>
<span id="t1w_246" class="t s5_246">http://www.ncbi.nlm.nih.gov/pubmed/7516093</span><span id="t1x_246" class="t s4_246">. </span>
<span id="t1y_246" class="t s4_246">634. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison </span>
<span id="t1z_246" class="t s4_246">of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus </span>
<span id="t20_246" class="t s4_246">cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or </span>
<span id="t21_246" class="t s4_246">metastatic squamous cell carcinoma of the head and neck. A phase III </span>
<span id="t22_246" class="t s4_246">study of the EORTC Head and Neck Cancer Cooperative Group. Ann </span>
<span id="t23_246" class="t s4_246">Oncol 1994;5:521-526. Available at: </span>
<span id="t24_246" class="t s5_246">http://www.ncbi.nlm.nih.gov/pubmed/7522527</span><span id="t25_246" class="t s4_246">. </span>
<span id="t26_246" class="t s4_246">635. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based </span>
<span id="t27_246" class="t s4_246">chemotherapy plus cetuximab in head and neck cancer. N Engl J Med </span>
<span id="t28_246" class="t s4_246">2008;359:1116-1127. Available at: </span>
<span id="t29_246" class="t s5_246">http://www.ncbi.nlm.nih.gov/pubmed/18784101</span><span id="t2a_246" class="t s4_246">. </span>
<span id="t2b_246" class="t s4_246">636. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or </span>
<span id="t2c_246" class="t s4_246">with chemotherapy versus cetuximab with chemotherapy for recurrent or </span>
<span id="t2d_246" class="t s4_246">metastatic squamous cell carcinoma of the head and neck (KEYNOTE- </span>
<span id="t2e_246" class="t s4_246">048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915- </span>
<span id="t2f_246" class="t s4_246">1928. Available at: </span><span id="t2g_246" class="t s5_246">https://www.ncbi.nlm.nih.gov/pubmed/31679945</span><span id="t2h_246" class="t s4_246">. </span>
<span id="t2i_246" class="t s6_246">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
